Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Approval to start Efti & Bavencio trial in urothelial cancer (ASX:IMM)

Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO®...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - March 2023 (ASX:IIQ)

Progress on EXO-NET® commercialisation with Academia and Industry INOVIQ presented on EXO-NET and exosomes to the Preterm Birth International Collaborative #PREBIC Aus...read more

icetana - Quarterly Appendix 4C Cash Flow Report (ASX:ICE)

To view the Appendix, download the attached PDF.

icetana - Quarterly Activities Report (ASX:ICE)

icetana Limited (ASX: ICE) (“icetana” or “the Company” or “we”), a global software company providing artificial intelligence solutions to detect real-time&nb...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancer ...read more

Immutep to announce new TACTI-002 data at ASCO 2023 (ASX:IMM)

Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA – 27 April 2023 – Immutep L...read more

Immutep appoints Dr Florian Vogl as Chief Medical Officer (ASX:IMM)

SYDNEY, AUSTRALIA – 26 April 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune...read more

Immutep - Response to ASX Aware Query (ASX:IMM)

By email only Dear Mr Zhao, Immutep Limited – Response to Query Letter I refer to your letter dated 5 April 2023 in relation to the ASX Query Letter. Immutep Limited ...read more

Immutep - Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma (ASX:IMM)

Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis First time efti will be studied in neoadjuvant, non-metastatic cancer setting...read more

Notification of cessation of securities - IMM (ASX:IMM)

To view the notification, download the attached PDF.

Immutep - Appendix 3Z - Lucy Turnbull (ASX:IMM)

To view the appendix, download the attached PDF.

Immutep - Appendix 3X - Lis Boyce (ASX:IMM)

To view the appendix, download the attached PDF.

Immutep Announces Changes to the Board (ASX:IMM)

SYDNEY, AUSTRALIA – 11 April 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing n...read more

icetana - Further Tamdeen expansion order (ASX:ICE)

Highlights: icetana has secured a further expansion order for its newly released AI video analytic solution from Tamdeen Mall Management. This is in addition to the expansion ord...read more

Immutep - Positive Final Data in 2nd Line Metastatic NSCLC Patients (ASX:IMM)

-- Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care chemotherapy -- 83...read more

Viewing: 166 - 180 of 200 Previous | Next